MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
+0.110
+8.21%
After Hours: 1.460 +0.01 +0.69% 16:34 02/21 EST
OPEN
1.360
PREV CLOSE
1.340
HIGH
1.460
LOW
1.350
VOLUME
399.30K
TURNOVER
--
52 WEEK HIGH
7.51
52 WEEK LOW
0.7400
MARKET CAP
60.01M
P/E (TTM)
-0.4435
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACRS stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 3.500.

EPS

ACRS News

More
  • Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
  • GlobeNewswire · 3d ago
  • TEVA, SHOP among premarket gainers
  • Seeking Alpha - Article · 02/12 14:08
  • Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
  • GlobeNewswire · 02/10 12:00
  • What Company Will Eli Lilly Buy Next?
  • MotleyFool.com · 01/23 12:00

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ACRS

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.
More

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.